A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2

Sponsor
Dana-Farber Cancer Institute (Other)
Overall Status
Recruiting
CT.gov ID
NCT03152318
Collaborator
National Institutes of Health (NIH) (NIH), Candel Therapeutics, Inc. (Industry)
56
Enrollment
2
Locations
2
Arms
76.5
Anticipated Duration (Months)
28
Patients Per Site
0.4
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This research study is evaluating an investigational drug, an oncolytic virus called rQNestin34.5v.2. This research study is a Phase I clinical trial, which tests the safety of an investigational drug and also tries to define the appropriate dose of the investigational drug as a possible treatment for this diagnosis of recurrent or progressive brain tumor.

Detailed Description

This research study is a Phase I clinical trial, which tests the safety of an investigational drug and also tries to define the appropriate dose of the investigational drug as a possible treatment for this diagnosis. "Investigational" means that the intervention is being studied.

The FDA (the U.S. Food and Drug Administration) has not approved rQNestin34.5v.2 as a treatment for any disease. This is the first time that rQnestin34.5v.2 will be given to humans.

The research drug, rQNestin34.5v.2, is an oncolytic viral vector made from the herpes simplex virus type 1 (HSV1). The large majority of humans already have regular HSV1 in their nervous system. Normally, this virus can cause cold sores in areas like the lips, fingers and genitals in humans by making copies of itself in normal healthy cells. In some cases, HSV1 can cause severe infection of the brain and liver and/or death. However, scientists have removed or changed parts of the rQNestin virus being used on this study so it can only make copies of itself in glioma cells and not normal healthy cells.

If it is effective, the rQNestin34.5v.2 drug will spread to a glioma cell, kill it, and then make a copy of itself and spread again. This should be repeated over and over until all glioma cells are reached. If rQNestin34.5v.2 moves into a normal brain cell, it should not grow and make copies, and therefore should not spread to other normal brain cells.

The purpose of this research study is to test if rQnestin34.5v.2 is safe to use in humans, and if it is effective in treating malignant glioma. This study is also looking for the highest dose of rQNestin34.5v.2 that can be given safely to people with malignant brain tumors.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
56 participants
Allocation:
Non-Randomized
Intervention Model:
Sequential Assignment
Intervention Model Description:
phase I, open-label, single center, dose-escalation, double arm clinical trial of an oncolytic virus called rQNestinphase I, open-label, single center, dose-escalation, double arm clinical trial of an oncolytic virus called rQNestin
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Phase I Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2, a Genetically Engineered HSV-1 Virus, and Immunomodulation With Cyclophosphamide
Actual Study Start Date :
Jul 18, 2017
Anticipated Primary Completion Date :
Dec 1, 2022
Anticipated Study Completion Date :
Dec 1, 2023

Arms and Interventions

ArmIntervention/Treatment
Experimental: Arm A- rQNestin

Arm A is rQNestin34.5v.2 treatment This study follows a standard 3+3 dose escalation design. Participants will not enroll to Arm B until the MTD or HTD has been met for Arm A. Subjects with presumed radiologic evidence of recurrent malignant glioma will undergo stereotactic biopsy under monitored general or local anesthesia. Evidence of recurrent high grade or malignant must be found on frozen section for the person to receive administration of the agent. rQNestin34.5v.2 Indicated dose as per cohort, Intratumor administration during surgery, single dose

Drug: rQNestin
rQNestin is an oncolytic viral vector. It is administered via intratumoral injection during biopsy surgery.
Other Names:
  • rQNestin34.5v.2
  • Procedure: Stereotactic biopsy
    In both arms, subjects will undergo standard of care stereotactic biopsy in the intraoperative MRI operating room. The stereotactic needle will be placed stereotactically into the tumor bed using intraoperative MRI guidance to collect the biopsy, and again to administer the rQNestin oncolytic virus.

    Experimental: Arm B- rQNestin+CPA

    Arm B is rQNestin34.5v.2 treatment with Cyclophosphamide (CPA) pre-treatment This study follows a standard 3+3 dose escalation design. Participants will not enroll to Arm B until the MTD or HTD has been met for Arm A. Cyclophosphamide one intravenous injection 2 days prior to procedure. Subjects with presumed radiologic evidence of recurrent malignant glioma will undergo stereotactic biopsy under monitored general or local anesthesia. Evidence of recurrent high grade or malignant must be found on frozen section for the person to receive administration of the agent. rQNestin34.5v.2 Indicated dose as per cohort, Intratumor administration during surgery, single dose

    Drug: rQNestin
    rQNestin is an oncolytic viral vector. It is administered via intratumoral injection during biopsy surgery.
    Other Names:
  • rQNestin34.5v.2
  • Drug: Cyclophosphamide
    Cyclophosphamide is an immunomodulating agent. It is administered intravenously in a single dose 2 days (+/- 6 hrs) before surgery.
    Other Names:
  • Cytoxan®
  • Neosar®
  • Procedure: Stereotactic biopsy
    In both arms, subjects will undergo standard of care stereotactic biopsy in the intraoperative MRI operating room. The stereotactic needle will be placed stereotactically into the tumor bed using intraoperative MRI guidance to collect the biopsy, and again to administer the rQNestin oncolytic virus.

    Outcome Measures

    Primary Outcome Measures

    1. Maximum Tolerated Dose [Minimum of 21 Days]

      The primary objective is to determine the maximum tolerated dose of rQNestin34.5v.2 injected into recurrent malignant gliomas, with or without previous immunomodulation with cyclophosphamide.

    Secondary Outcome Measures

    1. MRI Changes in Permeability [Evaluated every 2 months for 1 year]

      Determine MRI alterations of permeability in injected sites using standard perfusion sequences.

    2. MRI Changes in Volume [Evaluated every 2 months for 1 year]

      Determine MRI alterations of cerebral blood volume in injected sites using standard sequences.

    3. MRI Changes in Flow [Evaluated every 2 months for 1 year]

      Determine MRI alterations of cerebral blood flow in injected sites using standard sequences.

    4. Viral Shedding in Saliva [Evaluated up to day 56 for each subject]

      Assess the shedding of rQNestin34.5v.2 in the saliva of subjects treated with rQNestin34.5v.2

    5. HSV1 Viremia [Evaluated up to day 56 for each subject]

      Assess the degree of HSV-1 viremia post rQNestin34.5v.2 administration

    6. HSV1 Antibody Response [Evaluated up to day 56 for each subject]

      Identify changes in HSV1 antibody response

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • At the time of surgery, frozen biopsy confirmation of high grade or malignant glioma by neuropathologist. Biopsy confirmation of glioma or infiltrative glioma at time of surgery will be acceptable, provided that subject has prior pathology confirmation of high-grade glioma. If subject had previous diagnosis of low grade glioma, then the biopsy must show high grade glioma. To be confirmed at time of surgery, after registration in OnCore.

    • Participants must have prior diagnosis of glioma (astrocytoma, malignant astrocytoma, oligodendroglioma, anaplastic oligodendroglioma, mixed oligo-astrocytoma), exclusive of ependymoma, ganglioglioma, pylocytic/pylomyxoid astrocytoma as confirmed by a neuropathologist or by a previous local pathology report.

    • Prior history of external beam radiotherapy ≥ 5,000 cGy delivered to the tumor at least 4 weeks prior to registration. Participants over the age of 70 with prior history of hypofractionated external beam radiotherapy will also be accommodated, in accordance with NCCN guidelines; For participants with diagnosis of oliogodendroglioma or anaplastic oligodendroglioma, prior history of external beam radiotherapy < 5,000 cGy or no history of radiation are both acceptable

    • Prior history of temozolomide chemotherapy provided concurrent to external beam radiotherapy and after as per current standard of care. However, temozolomide would not be required to have been provided concomitantly or after radiation if the patient had unmethylated MGMT promoter or if the patient initially was diagnosed with a low grade glioma. At least 4 weeks must have passed from the last dose of temozolomide and first dose of cyclophosphamide and/or rQNestin34.5v.2; 3.1.4.1 For participants with diagnosis of oliogodendroglioma or anaplastic oligodendroglioma, chemotherapy may have been administered before, during, or after radiation or not at all.

    • If participant was treated with bevacizumab, at least 4 weeks must elapse before treatment with either agent (Cyclophosphamide or rQNestin34.5v.2);

    • Recurrent lesion must be ≥ 1.0 cm in diameter as determined by MRI;

    • Normal hematological, renal and liver function as defined below: Leukocytes ≥3,000/mcL; Absolute lymphocyte count > 500/ mcL; Absolute neutrophil count ≥1,500/mcL; platelets ≥100,000/mcL; PT or PTT <1.5 x institutional upper limit; Hemoglobin >10.0 g/dL; Total serum bilirubin within normal institutional limits; AST(SGOT)/ALT(SGPT) ≤2.5 × institutional upper limit of normal; Serum creatinine within normal institutional limits OR Creatinine clearance ≥60 mL/min/1.73 m2 for participants with creatinine levels above institutional normal;

    • Karnofsky Performance Score ≥70.

    • Age ≥ 18 years;

    • Ability to understand and the willingness to sign a written informed consent document;

    • The effects of rQNestin34.5v.2 and cyclophosphamide on the developing human fetus are unknown. For this reason and because cytotoxic & immunomodulating agents as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation including 3 months following the study. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study and for the duration of study participation including 3 months following the study. Women of child-bearing potential must have a negative serum pregnancy test within 48 hours of study registration.

    • Steroid regimen stable or decreasing for at least 7 days prior to inoculation;

    • Ability to undergo MRI scanning with contrast;

    • Subjects with any recurrence (first, second, third, etc recurrence) will be able to be enrolled.

    Exclusion Criteria:

    Participants who exhibit any of the following conditions prior to initiating study treatment will not be eligible for this study:

    • Participants with significant renal or liver disease

    • Participants with progressive systemic malignancy.

    • Known chronic infections with HIV, hepatitis B or C; participants with a history of resolved Hepatitis A may be included in the trial.

    • Participants with active viral, bacterial or fungal infection requiring concurrent antiviral or antibiotics.

    • Subjects with active HSV1 infection on current valacyclovir, acyclovir or ganciclovir therapy must be off treatment with any of these agents at least 7 days prior to surgery.

    • History of allergic reactions attributed to compounds of similar chemical or biologic composition to cyclophosphamide (only for arm B).

    • Active, known, or suspected immunosuppressive disorders, such as acquired or congenital immune deficiency syndromes and autoimmune diseases

    • Unacceptable anesthesia risk

    • Serious cardiopulmonary medical condition

    • Pregnant or lactating females

    • Recurrent glioma where injection in either arm A or B of the biologic agent would require access and/or considerable spillage into the ventricular system.

    • Prior participant in another protocol using an investigational agent or device within 5 half-lives or 4 weeks of the investigational agent, whichever is shorter.

    • Known HIV seropositivity.

    • Concurrent therapy with drugs active against HSV (acyclovir, valaciclovir, penciclovir, famciclovir, ganciclovir, foscarnet, cidofovir). Participants must be off treatment with these agents for at least 7 days prior to surgery.

    • Active oral or genital herpes lesions.

    • Participants who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.

    • Participants who are receiving any other investigational agents. Previous rQNestin34.5v.2 participants may be re-enrolled if they completed at least the day 56 assessment without DLT.

    • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

    • Participants with tumor ≤ 1 cm proximity to the ventricles will be allowed to enroll. However the study agent (rQNestin34.5v.2) may not be injected in any area that is within 1 cm of the ventricle regardless of where the tumor is located.

    Contacts and Locations

    Locations

    SiteCityStateCountryPostal Code
    1Dana Farber Cancer InstituteBostonMassachusettsUnited States02115
    2Brigham and Women's HospitalBostonMassachusettsUnited States02215

    Sponsors and Collaborators

    • Dana-Farber Cancer Institute
    • National Institutes of Health (NIH)
    • Candel Therapeutics, Inc.

    Investigators

    • Principal Investigator: E. Antonio Chiocca, MD, PhD, Brigham and Women's Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    E. Antonio Chiocca, Principal Investigator, Dana-Farber Cancer Institute
    ClinicalTrials.gov Identifier:
    NCT03152318
    Other Study ID Numbers:
    • 16-557
    First Posted:
    May 15, 2017
    Last Update Posted:
    Aug 11, 2021
    Last Verified:
    Aug 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by E. Antonio Chiocca, Principal Investigator, Dana-Farber Cancer Institute
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 11, 2021